A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)

Stopped Change in the benefit-risk balance

Conditions

• Neonatal Respiratory Distress Syndrome

Interventions

• DRUG: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)
• DRUG: nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)
• OTHER: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)
• OTHER: nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)

Sponsor

Chiesi Farmaceutici S.p.A.